Presentation Alert: Aethlon Medical Presentation at Rodman & Renshaw Conference To Be Webcast ``Live'' on Monday, June 19th

SAN DIEGO--June 15, 2006--Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, disclosed today that its Chairman and CEO, James A. Joyce, will present at the Rodman & Renshaw 3rd Annual Security, Biodefense & Connectivity Conference on June 19th, 2006. The conference will take place at the St. Regis Hotel in New York City. Mr. Joyce's presentation is scheduled to begin at 4:30pm EST and will be available to access online through a "live" web-cast at www.wsw.com/webcast/rrshq9/aemd.ob.

About the Conference

The conference, which brings together over 60 emerging growth security and connectivity companies, is a unique opportunity for companies to showcase their technologies and for the investment community to access some of the most exciting opportunities in the security and connectivity space. This is a great opportunity to witness companies, evolving from cutting edge, innovative research platforms to companies with products paramount to today's needs. More than 600 delegates, including institutional investors, venture capitalists, and senior corporate executives as well as experts from the scientific and government communities, are registered to attend the event.

The chosen companies will present their strategies, product portfolios and financial outlook in an array of security markets including biometrics, digital network protection and physical & perimeter security. The format of the Conference will include company presentations, breakout sessions, and one-on-one meetings with presenting companies, as well as a featured guest speaker, General Wesley Clark.

About Rodman & Renshaw

Rodman & Renshaw, LLC is a privately held, full-service investment bank committed to fostering the long-term success of emerging growth companies through capital raising, strategic advice, insightful research, and the development of institutional support. During the last two years, Rodman & Renshaw completed over 60 financing transactions, totaling over $1 billion. Rodman & Renshaw concentrates on emerging growth companies in the life science and technology sectors.

About Aethlon Medical

Aethlon Medical is developing the first medical device to treat infectious disease. The device, known as the Hemopurifier(TM), is a broad-spectrum treatment countermeasure against drug and vaccine resistant bioweapons, naturally evolving pandemic threats such as H5N1 Avian Flu, and chronic infectious disease targets including Hepatitis-C (HCV) and the Human Immunodeficiency Virus (HIV). Global researcher, Frost & Sullivan, recently awarded the Hemopurifier(TM) the 2006 Technology Innovation Award for its advances in the field of biodefense. Aethlon has also initiated research on a second generation Hemopurifier(TM) that targets the capture of growth factors inherent in the spread of Cancer. More information on Aethlon Medical and the Hemopurifier(TM) technology can be found at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.